Meeting
2020 ASCO Virtual Scientific Program
Escalation portion of phase II study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K/mTOR inhibitor paxalisib (GDC-0084) in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status.
Authors
Patrick Y. Wen
Dana-Farber Cancer Institute, Boston, MA
Patrick Y. Wen , John Frederick De Groot , James D. Battiste , Samuel Aaron Goldlust , James Stuart Garner , Jeremy Andrew Simpson , Jelle Kijlstra , Alan Olivero , Timothy Francis Cloughesy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT03522298
Citation
J Clin Oncol 38: 2020 (suppl; abstr 2550)
DOI
10.1200/JCO.2020.38.15_suppl.2550
Abstract #
2550
Poster Bd #
41
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: Final phase 2 study results.
First Author: Patrick Y. Wen
Poster
2016 ASCO Annual Meeting
A first-in-human phase 1 study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma.
First Author: Patrick Y. Wen
Poster
2016 ASCO Annual Meeting
Phase I/II study of VAL-083 in patients with recurrent glioblastoma.
First Author: Kent C. Shih
Poster
2013 ASCO Annual Meeting
Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM).
First Author: Patrick Y. Wen